Close Menu

NEW YORK – Clinical genetics firm Blueprint Genetics and rare disease diagnostics company Archimedlife Medical Laboratory said today that they have partnered to offer biochemical testing for rare diseases in North America.

Under the agreement, Blueprint Genetics is licensing Archimedlife's technology and tests to offer biochemical testing at its Seattle laboratory, which also provides next-gen sequencing-based genetic testing. The combined testing services will be available in early 2020.

Financial terms and other details of the partnership were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.